Table 1.
Summary of studies on the use of locoregional therapy for cholangiocarcinoma.
| Reference | Patients | Treatment | Responders | Median PFS (Months) | Median OS (Months) | Tumor Progression (%) |
|---|---|---|---|---|---|---|
| Han et al. (2015) [24] | 84 | Radiofrequency Ablation | - | - | 1-year survival rate—82% (95% CI 72–90%) 3-year survival rate—47% (95% CI 28–65%) 5-year survival rate—24% (95% CI 11–40% |
21% (CI 95% 13–30%) |
| Moole et al. (2017) [25] | 297 | Photodynamic Therapy | - | - | 13.6 months (95% CI 11.47–15.67) | - |
| Herber et al. (2007) [28] | 15 | TACE | - | - | 21.1 months (95% CI 9.4–32.5 months) | 4/15 patients—8.2% |
| Vogl et al. (2012) [29] | 115 | TACE | Partial Response 8.7% | 7 months | 13 months | - |
| Edeline et al. (2019) [30] | 41 | Selective Internal Radiotherapy | 41% (95% CI 28–55%) | 14 months (95% CI 8–17 months) | 22 months (95% CI 14–52 months) | - |
| Zhang et al. (2016) [34] | 107 | MWA | - | 8.9 months (95% CI 6.5–11.3 months) | 28.0 months (95% CI 23.7–32.2 months) | - |
| Yu et al. (2011) [35] | 15 | MWA | - | - | 10 months | 25% (6/24 nodules total in 15 patients) |
| Ohkawa et al. (2014) [39] | 20 | Proton Beam Therapy | - | - | 27.5 months in curative group 9.6 months in palliative group |
- |
| Hong et al. (2016) [40] | 37 | Proton Beam Therapy | - | 8.4 months (95% CI 5–15.7 months) | 22.5 (95% CI 12.4–49.7 months) | - |
| Frankulli et al. (2019) [41] | 182 | Stereotactic Body Radiation | - | - | 1-year survival rate of 57.1% (95% CI 45–58%) | - |
| Queen et al. (2014) [42] | 106 | Endoscopy | - | - | 2.89 months (95% CI 0.09–30 months) | - |